TSEC:1795

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Lotus Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells medicines in Taiwan, Korea, the United States, and internationally. More Details


Snowflake Analysis

Proven track record and fair value.


Similar Companies

Share Price & News

How has Lotus Pharmaceutical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1795 is less volatile than 75% of TW stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: 1795's weekly volatility (3%) has been stable over the past year.


Market Performance


7 Day Return

-4.3%

1795

-0.9%

TW Pharmaceuticals

2.0%

TW Market


1 Year Return

-32.3%

1795

31.8%

TW Pharmaceuticals

31.2%

TW Market

Return vs Industry: 1795 underperformed the TW Pharmaceuticals industry which returned 31.8% over the past year.

Return vs Market: 1795 underperformed the TW Market which returned 31.2% over the past year.


Shareholder returns

1795IndustryMarket
7 Day-4.3%-0.9%2.0%
30 Day-13.3%-8.0%10.6%
90 Day-12.9%-15.2%22.8%
1 Year-32.3%-32.3%34.1%31.8%35.8%31.2%
3 Year42.7%42.7%39.5%31.9%58.3%40.5%
5 Year7.5%7.5%10.5%2.0%133.0%92.1%

Long-Term Price Volatility Vs. Market

How volatile is Lotus Pharmaceutical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Lotus Pharmaceutical undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 1795 (NT$70.4) is trading below our estimate of fair value (NT$837.79)

Significantly Below Fair Value: 1795 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 1795 is poor value based on its PE Ratio (20.2x) compared to the TW Pharmaceuticals industry average (17.9x).

PE vs Market: 1795 is poor value based on its PE Ratio (20.2x) compared to the TW market (18.6x).


Price to Earnings Growth Ratio

PEG Ratio: 1795 is good value based on its PEG Ratio (0.6x)


Price to Book Ratio

PB vs Industry: 1795's PB Ratio (2.1x) is in line with the TW Pharmaceuticals industry average.


Next Steps

Future Growth

How is Lotus Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

33.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1795's forecast earnings growth (33.2% per year) is above the savings rate (0.8%).

Earnings vs Market: 1795's earnings (33.2% per year) are forecast to grow faster than the TW market (18.7% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 1795's revenue (6.8% per year) is forecast to grow slower than the TW market (11.2% per year).

High Growth Revenue: 1795's revenue (6.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 1795's Return on Equity is forecast to be low in 3 years time (11.7%).


Next Steps

Past Performance

How has Lotus Pharmaceutical performed over the past 5 years?

58.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1795 has high quality earnings.

Growing Profit Margin: 1795's current net profit margins (8.2%) are higher than last year (7.3%).


Past Earnings Growth Analysis

Earnings Trend: 1795 has become profitable over the past 5 years, growing earnings by 58.6% per year.

Accelerating Growth: 1795's earnings growth over the past year (42.2%) is below its 5-year average (58.6% per year).

Earnings vs Industry: 1795 earnings growth over the past year (42.2%) exceeded the Pharmaceuticals industry 23.3%.


Return on Equity

High ROE: 1795's Return on Equity (10.3%) is considered low.


Next Steps

Financial Health

How is Lotus Pharmaceutical's financial position?


Financial Position Analysis

Short Term Liabilities: 1795's short term assets (NT$5.8B) exceed its short term liabilities (NT$4.0B).

Long Term Liabilities: 1795's short term assets (NT$5.8B) do not cover its long term liabilities (NT$6.3B).


Debt to Equity History and Analysis

Debt Level: 1795's debt to equity ratio (79.7%) is considered high.

Reducing Debt: 1795's debt to equity ratio has increased from 55.7% to 79.7% over the past 5 years.

Debt Coverage: 1795's debt is well covered by operating cash flow (22.8%).

Interest Coverage: 1795's interest payments on its debt are well covered by EBIT (4.6x coverage).


Balance Sheet


Next Steps

Dividend

What is Lotus Pharmaceutical current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 1795's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 1795's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1795's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1795's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1795's dividend in 3 years as they are not forecast to pay a notable one for the TW market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average management tenure


CEO

Petar Vazharov

3yrs

Tenure

NT$12,828,000

Compensation

Mr. Petar Antonov Vazharov is Executive Vice President of the Asia Pacific Region of Alvogen Group. He is General Manager of Alvogen Korea Holdings Ltd. He is a Director of Alvogen Korea Co., Ltd., Alvogen...


CEO Compensation Analysis

Compensation vs Market: Petar's total compensation ($USD457.95K) is about average for companies of similar size in the TW market ($USD442.53K).

Compensation vs Earnings: Insufficient data to compare Petar's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Petar Vazharov
GM & Director3yrsNT$12.83mno data
Eeling Chan
Chief Financial Officer4.17yrsNT$5.19mno data
Bjartur Shen
VP / Deputy General Manager of Strategy & Finance3yrsNT$10.35mno data
Stanley Gu
Country Manager3yrsNT$5.82mno data
Zenon Zdunek
Vice President of Supply Chain & Operations1.5yrsno data0.0057%
NT$ 990.5k
Angela Luan
Corporate Finance & Regional Investor Relations Directorno datano datano data
Saral Thangam
Chief Executive Officer of Norwich Clicial Servicesno datano datano data
Yao Le Hong
Vice Presidentno datano datano data
Charles Lin
Strategic Consultant4.08yrsno datano data

3.0yrs

Average Tenure

Experienced Management: 1795's management team is considered experienced (3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Petar Vazharov
GM & Director3yrsNT$12.83mno data
Hjorleifur Palsson
Independent Director5.75yrsNT$898.00no data
Robert Wessman
Chairman2.08yrsno datano data
Thor Kristjansson
Director6.33yrsno datano data
Hirofumi Imai
Director1.58yrsno datano data
Arni Hardarson
Director6.33yrsno datano data
Kevin Bain
Director3.5yrsno datano data
Benjamin Ku
Independent Director6.33yrsNT$750.00no data
Han-Fei Lin
Independent Director4.58yrsNT$640.000.0029%
NT$ 494.4k
Joel Morales
Director1.83yrsno datano data

5.2yrs

Average Tenure

Experienced Board: 1795's board of directors are considered experienced (5.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Lotus Pharmaceutical Co., Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Lotus Pharmaceutical Co., Ltd.
  • Ticker: 1795
  • Exchange: TSEC
  • Founded: 1966
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: NT$17.347b
  • Shares outstanding: 245.35m
  • Website: https://www.lotuspharm.com.tw

Number of Employees


Location

  • Lotus Pharmaceutical Co., Ltd.
  • No. 277 Song Ren Road
  • Xin Yi District
  • Taipei
  • 110
  • Taiwan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
1795TSEC (Taiwan Stock Exchange)YesShare CapitalTWTWDAug 2014

Biography

Lotus Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells medicines in Taiwan, Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of o...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/26 08:42
End of Day Share Price2021/01/26 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.